$3.13
1.73% today
Nasdaq, Sep 16, 08:19 pm CET
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Fulcrum Therapeutics Inc Stock price

$3.18
-5.99 65.32% 1M
-8.18 72.01% 6M
-3.57 52.89% YTD
-1.57 33.05% 1Y
-23.12 87.91% 3Y
-6.82 68.20% 5Y
-10.32 76.44% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
-0.26 7.56%
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Key metrics

Market capitalization $198.43m
Enterprise Value $-65.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 5.21
EV/Sales (TTM) EV/Sales -0.80
P/S ratio (TTM) P/S ratio 2.43
P/B ratio (TTM) P/B ratio 0.72
Revenue growth (TTM) Revenue growth 2,582.55%
Revenue (TTM) Revenue $81.63m
EBIT (operating result TTM) EBIT $-32.77m
Free Cash Flow (TTM) Free Cash Flow $-12.62m
Cash position $273.78m
EPS (TTM) EPS $-0.35
P/E forward negative
P/S forward 2.47
EV/Sales forward negative
Short interest 16.08%
Show more

Is Fulcrum Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Fulcrum Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Fulcrum Therapeutics Inc forecast:

2x Buy
25%
5x Hold
63%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Fulcrum Therapeutics Inc forecast:

Buy
25%
Hold
63%
Sell
13%

Financial data from Fulcrum Therapeutics Inc

Assets
Jun '24
280 280
Cash 274 274
Claims 3.53 3.53
Inventories - -
Other current assets Other current assets Current assets 2.97 2.97
14 14
Property, plant and equipment 11 11
Financial assets 1.22 1.22
Intangible Assets - -
Other fixed assets Other assets Fixed assets 1.99 1.99
Total Assets 294 294
Liabilities
Jun '24
Equity 274 274
20 20
Current liabilities 13 13
Non-current liabilities 7.77 7.77
Total Capital 294 294

In millions USD.

Don't miss a Thing! We will send you all news about Fulcrum Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulcrum Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of t...
Negative
Invezz
4 days ago
Fulcrum Therapeutics Inc. (NASDAQ: FULC) saw its stock plunge 65% on Thursday after announcing that its late-stage trial for losmapimod, a treatment for facioscapulohumeral muscular dystrophy (FSHD), failed to meet its primary endpoint. This significant setback has led the biotech company to halt further development of the drug for FSHD, causing its stock to nosedive.
Neutral
GlobeNewsWire
4 days ago
― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ―
More Fulcrum Therapeutics Inc News

Company Profile

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Sapir
Employees 76
Founded 2015
Website www.fulcrumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today